Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip - an inactivated split virion influenza vaccine - supports wider vaccine use

Vaccine

Volumn 25, Issue 45, 2007, Pages 7720-7731

  Arnoux, Sabine ^a   Weinberger, Clement ^a   Gessner, Bradford D ^b  

^a SANOFI PASTEUR   (France)

^b Agence de Medecine Preventive   (France)

Author keywords

Clinical trials; Inactivated influenza vaccine; Influenza; Influenza vaccine; Review; Vaccine effectiveness; Vaccine preventable incidence

Indexed keywords

GRIPPOL; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DEATH; DRUG EFFICACY; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; INFLUENZA; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRION;

ANTIBODIES, VIRAL; CLINICAL TRIALS AS TOPIC; COST OF ILLNESS; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VACCINES, INACTIVATED;

EID: 35348965221     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.063     Document Type: Review

References (55)

1. Bridges C.B., Harper S.A., Fukuda, Uyeki T.M., Cox N.J., and Singleton J.A. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 52 RR08 (2003) 1-36
2. Nichol K.L., Lind A., Margolis K.L., Murdoch M., McFadden R., Hauge M., et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 333 (1995) 889-893
3. Neuzil K.M., Dupont W.D., Wright P.F., and Edwards K.M. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 20 (2001) 733-740
4. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 338 (1998) 1405-1412
5. Nichol K.L., Margolis K.L., Wuorenma J., and Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 331 (1994) 778-784
6. Nichol K.L., Nordin J., Mullooly J., Lask R., Fillbrandt K., and Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 348 (2003) 1322-1332
7. Hak E., Nordin J., Wei F., Mullooly J., Poblete S., Strikas R., et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 35 (2002) 370-377
8. Mangtani P., Cumberland P., Hodgson C.R., Roberts J.A., Cutts F.T., and Hall A.J. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database. J Infect Dis 190 (2004) 1-10
9. McBean A.M., Babish J.D., and Warren J.L. The impact and cost of influenza in the elderly. Arch Intern Med 153 (1993) 2105-2111
10. Beyer W.E.P. Heterogeneity of case definitions used in vaccine effectiveness studies-and its impact on meta-analysis. Vaccine 24 (2006) 6602-6604
11. Nichol K.L. Heterogeneity of influenza case definitions and implications for interpreting and comparing study results. Vaccine 24 (2006) 6726-6728
12. Bridges C.B., Thompson W.W., Melzer M.I., Reeve G.R., Talamonti W.J., Cox N.J., et al. Effectiveness and cost-benefit of influenza vaccination of health working adults. JAMA 284 (2000) 1655-1663
13. Foster D.A., Talsma A., Furumoto-Dawson A., Ohmit S.E., Margulies J.R., Arden N.H., et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 136 (1992) 296-307
14. Wood S.C., Alexseiv A., and Nguyen V.H. Effectiveness and economical impact of vaccination against influenza among a working population in Moscow. Vaccine 17 Suppl. 3 (1999) S81-S87
15. Jianping H., Xin F., Changshun L., Bo Z., Linxiu G., Wei X., et al. Assessment of effectiveness of Vaxigrip. Vaccine 17 Suppl. 1 (1999) S57-S58
16. European Agency for the Evaluation of Medicinal Products (EMEA). Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines CPMP/BWP/214/96. London: The European Agency for the Evaluation of Medicinal Products, 1997. Accessed at: http://www.emea.eu.int/pdfs/human/bwp/021496en.pdf.
17. Fukuda K., Levandowski R.A., Bridges C.B., and Cox N. Inactivated influenza vaccines. In: Plotkin S.A., Orenstein W.A., and Zorab R. (Eds). Vaccines. 4th ed. (2004), WB Saunders, Philadelphia, PA 339-370 [chapter 17]
18. Nichol K.L., Wuorenma J., and von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 158 (1998) 1769-1776
19. Negri E., Colombo C., Giordano L., Groth N., Apolone G., and La Vecchia C. Influenza vaccine in healthy children: a meta-analysis. Vaccine 23 (2005) 2851-2861
20. Morales A., Martinez M.M., Tasset-Tisseau A., Rey E., Baron-Papillon F., and Follet A. Costs and benefits of influenza vaccination and work productivity in a Colombian company from the employer's perspective. Value Health 7 (2004) 433-441
21. Samad A.H., Haji Usul M.H.B., Zakaria D., Ismail R., Tasset-Tisseau A., Baron-Papillon F., et al. Influenza vaccination in a Malaysian company: what are costs and benefits for the employer?. In: Kawaoka Y. (Ed). International Congress Series, vol. 1263. Options for the Control of Influenza V (2004), Elsevier, Amsterdam, NL 585-589
22. Santoro N., Tasset-Tisseau A., Nicoloyannis N., and Armoni J. Nine years of influenza vaccination in an Argentinean company: costs and benefits for the employer. In: Kawaoka Y. (Ed). International Congress Series, vol. 1263. Options for the Control of Influenza V (2004), Elsevier, Amsterdam, NL 590-594
23. Liu Y.H., Huang L.M., and Wang J.D. Reduction of acute respiratory illness (ARI) due to a voluntary workplace influenza vaccination program: who are more likely to get the benefit. J Occup Health 46 (2004) 455-460
24. National Advisory Committee on Immunization (NACI). Statement On Travel, Influenza, and Prevention. Canada Communicable Disease Report 2005;31-ACS-2:1-8.
25. Balkhy H., Memish Z., Bafaqeer S., and Almuneef M.A. Influenza a common viral infection among Hajj pilgrims: time for routine surveillance and vaccination. J Travel Med 11 (2004) 82-86
26. Qureshi H., Gessner B.D., Leboulleux D., Hasan H., Alam S.E., and Moulton L.H. The incidence of vaccine-preventable influenza-like illness and medication use among Pakistani pilgrims to the Haj in Saudi Arabia. Vaccine 18 (2000) 2956-2962
27. Mustafa A.N., Gessner B.D., Ismail R., Yusoff A.F., Abdullah N., Ishak I., et al. A case-control study of influenza vaccine effectiveness among Malaysian pilgrims attending the Haj in Saudi Arabia. Int J Infect Dis 7 (2003) 210-214
28. Merlin M., and Buisson A. L'évaluation de l'éfficacité de la vaccination antigrippale dans les armées au cours de l'hiver 1989-1990. BEH 41 (1990) 1975-1976
29. Pyhälä R., Haanpaa M., Kleemola M., Tervahauta R., Visakorpi R., and Kinnunen L. Acceptable protective efficacy of influenza vaccination in young military conscripts under circumstances of incomplete antigenic and genetic match. Vaccine 19 (2001) 3253-3260
30. Burtseva E.I., Vlasova L.N., Shevchenko E.S., Sabanin IuV, Rikhter V.V., Artiukov R.M., et al. [Evaluation of influenza vaccine Vaxigrip in the combined immunization of conscripts during influenza seasons of 2002-2003]. Zh Mikrobiol Epidemiol Immunobiol (2004) 49-55
31. Wang C.S., Wang S.T., and Chou P. Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community. Vaccine 20 (2002) 2494-2499
32. Hui S.L., Chu L.W., Peiris J.S.M., Chan K.H., Chu D., and Tsui W. Immune response to influenza vaccination in community-dwelling Chinese elderly persons. Vaccine 24 (2006) 5371-5380
33. Wongsurakiat P., Maranetra K.N., Wasi C., Kositanont U., Dejsomritrutai W., and Charoenratanakul S. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 125 (2004) 2100-2120
34. Ivanova V.T., Burseva E.I., Slepushkin A.N., Oskerko T.A., Zagorskaia Iu.V., Shevchenko E.S., et al. Comparative evaluation of the reactogenicity and immunogenicity of inactivated influenza vaccines in the elderly. Zh Mikrobiol Epidemiol Immunobiol September-October (5) (2000) 40-45
35. Gonzalez M., Pirez M.C., Ward E., Dibarboure H., Garcia A., and Picolet H. Safety and immunogenicity of a paediatric presentation of an influenza vaccine. Arch Dis Child 83 (2000) 488-491
36. Morales A., Arias Salazar J., Salazar Y., Garcia A., Arnoux S., Arancibia A., et al. A randomized controlled trial comparing split and subunit influenza vaccines in adults in Colombia. Medicina (B Aires) 63 (2003) 197-204
37. Lina B., Fletcher M.A., Valette M., Saliou P., and Aymard M. A TritonX-100-split virion influenza vaccine is safe and fulfills the Committee for Proprietary Medicinal Products (CPMP) recommendations for the European Community for Immunogenicity in Children. Adults and the Elderly Biologicals 28 (2000) 95-103
38. Beran J., Prymula R., Chlibek R., Rychly R., Splino M., Douda P., et al. Evaluation of reactogenicity and immunogenicity of two influenza vaccines (Vaxigrip and Fluarix) in the season 1996-1997. Cent Eur J Public Health 6 (1998) 269-273
39. Avila Aguero ML, Soriano-Fallas A, Umaña-Sauma MA, Ulloa-Gutierrez R, Arnoux S. Immunogenicity and tolerability of inactivated influenza vaccine in high risk and healthy children. Medicina (Buenos Aires) 2007;67, in press.
40. Zaplatnikov A.L., Burtseva Y.E.I., Korovina N.A., Vlasova L.N., Ivanova V.T., Dalechin V.I., et al. Efficiency of influenza vaccine prophylaxis in preschool children at the peak of morbidity of influenza and other acute respiratory viral infections. Russian J Pediatr 1 (2003) 34-38
41. Burtseva E.I., Zaplatnikov A.L., Shamsheva O.V., Rikhter V.V., Shevchenko E.S., and Slepushkin A.N. The Russian experience with Vaxigrip™ influenza split-virion vaccine in high-risk populations. Influenza Vaccines for the World. Lisboa (2004) [Abstract 23]
42. Squarcione S., Sgricia S., Biasio L.R., and Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 21 (2003) 1268-1274
43. Menegon T., Baldo V., Bonello C., Dalla Costa D., Di Tommaso A., and Trivello R. Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population. Eur J Epidemiol 15 (1999) 573-576
44. Baldo V., Menegon T., Bonello C., Floreani A., and Trivello R. "Mariutto" Collaborative Group. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 19 (2001) 3472-3475
45. Baldo V., Baldovin T., Floreani A., Minuzzo M., and Trivello R. Response to influenza vaccine in people with non-protective HI antibody titers. Eur J Epidemiol 21 (2006) 843-845
46. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mort Wkly Rep 55 (2006) RR1-RR48
47. World Health Organization. Influenza vaccines. Wkly Epidemiol Rec 33 (2005) 279-288
48. Rothberg M.B., and Rose D.N. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 118 (2005) 68-77
49. Lee P.Y., Matchar D.B., Clements D.A., Huber J., Hamilton J.D., and Peterson E.D. Economic analysis of influenza vaccination and antiviral treatment healthy working adults. Ann Intern Med 137 (2002) 225-231
50. Castilla J., Arrequi L., Baleztena J., Barricarte A., Brugos A., and Carpintero M. Incidence of influenza and influenza vaccine effectiveness in the 2004-2005 season. An Sist Sanit Navar 29 (2006) 97-106
51. King J.C., Stoddard J.J., Gaglani M.J., Moore K.A., Magder L., McClure E., et al. Effectiveness of school-based influenza vaccination. N Engl J Med 355 (2006) 2523-2532
52. Navas E., Salleras L., Dominquez A., Ibanez D., Prat A., Sentis J., et al. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives. Vaccine (2007) epub.
53. Audsley J.M., and Tannock G.A. The role of cell culture vaccines in the control of the next influenza pandemic. Expert Opin Biol Ther 4 (2004) 709-717
54. Gessner B.D., Sutanto A., Linehan M., Djelantik I.G., Fletcher T., Gerudug I.K., et al. Incidences of vaccine-preventable Haemophilus influenzae type bpneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet 365 (2005) 43-52
55. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomized, double-blind, placebo-controlled trial. Lancet 365 (2005) 1139-1146